Wondering if your Brazilian health plan has to cover Ozempic or Mounjaro? Here is what the ANS rules actually determine about GLP-1 medication coverage and what patients can do.
If you have been trying to get your health plan to cover Ozempic or Mounjaro, you probably already know how frustrating the process can feel. You have a prescription from your doctor, the medication has ANVISA approval, and yet your plan keeps saying no. So what gives? The answer lies in understanding how the ANS (Agência Nacional de Saúde Suplementar) actually works, and the gap between what is approved by regulators and what plans are required to pay for.
The Regulatory Framework — What the ANS Actually Requires
The ANS operates under a structured system that defines exactly what health plans must cover. The Rol de Procedimentos e Eventos em Saúde establishes the mandatory minimum list of procedures and medications that health plan operators are obligated to provide. This list gets updated periodically, and coverage obligations are tied directly to what appears on the active Rol at the time you submit your request.
Here is the key point many patients miss: ANVISA approval of a medication does not automatically translate into mandatory health plan coverage. Those are separate regulatory processes governed by different agencies. Ozempic (semaglutide) and Mounjaro (tirzepatide) have regulatory approval from ANVISA, but the ANS conducts its own evaluation process before adding any medication to the mandatory coverage list. As of the most recent Rol update, neither semaglutide nor tirzepatide appears on the list for weight loss purposes, which creates the central legal tension driving most coverage disputes.
The Critical Distinction — Diabetes Treatment vs. Weight Loss Indication
Ozempic received ANVISA approval specifically for treating type 2 diabetes, which means health plans have a clearer legal argument for coverage when the medication is prescribed for that indication. Mounjaro (tirzepatide) followed a similar path, securing ANVISA approval in 2023 for type 2 diabetes treatment as well. This distinction matters enormously in coverage disputes.
When these medications are prescribed for weight loss alone, without a formal diabetes diagnosis, the coverage obligation under the Rol becomes significantly weaker. Plans routinely deny these claims because the regulatory basis for mandatory coverage does not extend to obesity treatment at this time. Patients who have a documented diagnosis of type 2 diabetes, supported by HbA1c test results and an endocrinologist's prescription, are in a considerably stronger position when requesting coverage, even though the plan may still impose administrative hurdles along the way.
When Plans Are Expected to Cover — and When They Legally Can Refuse
Under the Rol de Procedimentos, plans must cover medications that appear on the list when they are prescribed for the conditions specified in the regulatory approval. This means Ozempic for diabetes has a stronger coverage argument than when it is used for obesity management. Plans may refuse coverage when the prescribed use does not match a listed indication, when the patient fails to provide required documentation, or when the medication is deemed not medically necessary by the plan's medical audit team.
However, plans cannot refuse coverage simply because the medication is expensive or because they prefer a cheaper alternative. If the prescribed medication meets the clinical criteria established by the Rol, cost considerations alone do not justify denial. The judicialization route has grown substantially in Brazil, with courts increasingly siding with patients when medical necessity is properly documented, even in cases involving off-label use for obesity management. If you want to stay updated on how these cases develop and what they mean for patients, OzemNews regularly covers changes in the regulatory landscape that affect coverage rights.
Documentation and the Step-by-Step Coverage Request Process
The coverage request process starts with your prescribing physician submitting a formal Laudo de Solicitação de Medicamento (LAUDO). This document must include your diagnosis, clinical justification, and prescription, and it serves as the foundation of any coverage claim you make.
Required attachments typically include recent HbA1c test results or metabolic panels, specialist evaluation notes from an endocrinologist, documentation of previous treatment attempts with standard medications, and your patient's enrollment history with the plan. The plan is required to respond within a defined period under the ANS resolution framework, and you have the right to file an administrative appeal if the initial request is denied.
If administrative appeals do not work, patients can file complaints directly with the ANS via the agency's official channels, or pursue mediation through consumer protection organizations to escalate the dispute. Keeping thorough records of all submissions and communications is essential throughout this process.
What Patients Can Realistically Do Right Now
Before requesting coverage, confirm your plan's specific contract terms. Some plans include extended coverage clauses that go beyond the minimum Rol requirements, and these can be decisive in individual cases. Reviewing your contract carefully before submitting a request can save you time and frustration.
Engaging an endocrinologist to produce a thorough clinical record with explicit medical justification significantly strengthens any coverage claim or appeal. Plans rely heavily on the quality of physician documentation when making coverage decisions, so a detailed LAUDO from a specialist carries more weight than a simple prescription. Keep copies of everything you submit and maintain records of all communication with the plan, including dates, protocol numbers, and the names of representatives you speak with.
Consulting with a health rights lawyer or a consumer protection organization can help you evaluate whether judicial action makes sense for your situation, particularly when the plan's denial appears to contradict your treating physician's clinical recommendation. OzemNews also provides resources that can help you understand your rights as a patient navigating the supplementary health system.
Key Facts to Understand Before Assuming Coverage or Denial
One of the most important things to understand is that ANVISA approval does not automatically mean mandatory coverage under the Brazilian supplementary health system. The ANS evaluates medications separately, considering clinical efficacy, cost-effectiveness, and epidemiological burden before adding anything to the mandatory coverage list.
The practical reality is that coverage depends heavily on your specific plan's contractual terms, your medical indication, and the quality of documentation you submit. There is no universal mandate from the ANS covering these medications for weight loss at this time, but the regulatory landscape may shift as the ANS continues to review metabolic treatments through its public consultation processes.
The bottom line is this: do not assume your plan will automatically cover these medications, but also do not assume they will never be covered. Each case depends on the specific circumstances, and understanding how the system works gives you the best chance of success.
FAQ
Does the ANS require health plans to cover Ozempic for type 2 diabetes?
Ozempic has ANVISA approval for type 2 diabetes, but it is not currently on the mandatory Rol de Procedimentos list. Coverage depends on your specific plan contract and the documentation provided. Plans cannot deny based on cost alone if clinical criteria are met.
Can I get Mounjaro covered if I have pre-diabetes or insulin resistance?
Coverage becomes more complicated outside of a formal type 2 diabetes diagnosis. These conditions are not currently listed as mandatory coverage indications under the Rol, which means plans generally have grounds to deny such requests, though judicial action remains an option.
What should I do if my plan denies coverage for Ozempic?
First, file an administrative appeal with all supporting documentation from your endocrinologist. If that fails, file a complaint with the ANS or seek mediation. If the medical justification is strong, pursuing the matter in court may be worthwhile.
Is the ANS considering adding GLP-1 medications to the mandatory coverage list?
The ANS periodically reviews the Rol through a structured evaluation process, and metabolic treatments have appeared on the regulatory agenda. However, no formal inclusion has been announced for obesity treatment with these medications at this time.
Where can I learn more about my coverage rights as a patient?
Resources like OzemNews provide ongoing coverage of regulatory changes and patient rights in the supplementary health system, helping you stay informed about what is happening and what options you have available.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Track your weight and your progress
Log weight, measurements and labs and see your progress in clear charts — because progress you don't measure is invisible progress.
or download the app
